Treatment
-
Forward Look
What’s Next? Winter 2019/2020Treating prostate cancer with fewer side effects.
by Bradley Jones
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
Avoiding Unnecessary Lymph Node BiopsyA study adds to evidence that many patients with ductal carcinoma in situ do not need to have their lymph nodes removed.
by Cheryl Platzman Weinstock
-
Learning the Language of ChemotherapyCancer patients often do not understand words their doctors use while talking about chemotherapy, but a new video series helps explain these terms.
by Jen Tota McGivney
-
Navigating Hospital Discharge DecisionsPatients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
-
Misunderstandings About Cancer DNA TestsMany cancer patients who received genomic testing of their cancers in a clinical trial did not fully understand the purpose of the testing.
by Emma Yasinski
-
September 27: The Week in Cancer NewsA study examines how poor and minority patients are more likely to be diagnosed with cancer in the emergency room, and a cancer survivor considers the lasting effects of chemotherapy.
by Bradley Jones
-
Forward Look
Measuring Treatment EffectivenessOutcomes are often evaluated using progression-free survival.
by Jasenka Piljac Zegarac
